Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.65 |
| ▸ | CDK4 | P11802 | 10/20 | 0.65 |
| ▸ | EIF2AK2 | P19525 | 6/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4615505 | 0.89 | CDK2 (0.67) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL5203801 | 0.79 | CDK2 (0.74) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL4615060 | 0.79 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL4613646 | 0.79 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL4613384 | 0.78 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL5201321 | 0.78 | CDK2 (0.60) | CDK2CDK4EIF2AK2 | |
| SCHEMBL5201949 | 0.77 | CDK2 (0.59) | CDK2CDK4EIF2AK2 | |
| SCHEMBL8317316 | 0.76 | CDK2 (0.74) | CDK2CDK4EIF2AK2 | |
| SCHEMBL6277071 | 0.75 | CDK2 (0.64) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL4616002 | 0.74 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262202-B2 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-28 | — | — | US | claimed |
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| EP-1373253-B1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | CYCLACEL LTD (GB) | 2007-06-20 | — | — | EP | claimed |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | US | claimed |
| US-7262202-B2 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1373253-B1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | CYCLACEL LTD (GB) | 2007-06-20 | — | — | EP | disclosed |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | US | disclosed |
| EP-1373253-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | Cyclacel Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002079193-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | CYCLACEL LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185134-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CDK2, CCNK, CDK3 | CDK2 1/4885CDK4 5/4885EIF2AK2 831/4885 |
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CDK2, CCNK, CDK3 | CDK2 1/4885CDK4 5/4885EIF2AK2 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.